Review

Gastroenterology and Hepatology

Volumn 6, Issue 1, 2010, Pages 57-59

  Ito, Tetsuhide ^a   Jensen, Robert T ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; PROTON PUMP INHIBITOR; SECRETIN;

ACHLORHYDRIA; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRINOMA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SURGERY; HUMAN; HYPERGASTRINEMIA; LIVER METASTASIS; LIVER RESECTION; LIVER TUMOR; MULTIPLE ENDOCRINE NEOPLASIA; NOTE; PEPTIC ULCER; PROGNOSIS; RADIOIMMUNOASSAY; STOMACH PH; TUMOR GROWTH; ZOLLINGER ELLISON SYNDROME;

EID: 76749146984     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (25)

1. Evans JT, Nickles S, Hoffman BJ. Primary hepatic gastrinoma: an unusual case of Zollinger-Ellison syndrome. Gastroenterol Hepatol. 2010;6:53-56.
2. Roy P, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore). 2000;79:379-411.
3. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep. 2004;6:454-463.
4. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85:295-330.
5. Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). 2006;85:331-364.
6. Roy P, Venzon DJ, Feigenbaum KM, Koviack PD, Bashir S, et al. Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis-a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore). 2001;80:189-222.
7. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine (Baltimore). 2004;83:43-83.
8. Corleto VD, Annibale B, Gibril F, Angeletti S, Serrano J, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther. 2001;15:1555-1561.
9. Dhillo WS, Jayasena CN, Lewis CJ, Martin NM, Tang KC, et al. Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists. Ann Clin Biochem. 2006;43:153-155.
10. Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep. 2009;11:433-441.
11. Goldman JA, Blanton WP, Hay DW, Wolfe MM. False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2009;7:600-602.
12. Jensen RT. Zollinger-Ellison syndrome. In: Doherty GM, Skogseid B, eds. Surgical Endocrinology: Clinical Syndromes. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2001:291-344.
13. Gibril F, Jensen RT. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep. 2005;7: 114-121.
14. Abou-Saif A, Lei J, McDonald TJ, Chakrabarti S, Waxman IF, et al. A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer. Gastroenterology. 2001;120:1271-1278.
15. Gibril F, Curtis LT, Termanini B, Fritsch MK, Lubensky IA, et al. Primary cardiac gastrinoma causing Zollinger-Ellison syndrome. Gastroenterology. 1997; 112:567-574.
16. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635-644.
17. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg. 2003;237:650-659.
18. Norton JA, Doherty GM, Fraker DL, Alexander HR, Doppman JL, et al. Surgical treatment of localized gastrinoma within the liver: a prospective study. Surgery. 1998;124:1145-1152.
19. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84:173-182.
20. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg. 2004;239:617-626.
21. Fishbeyn VA, Norton JA, Benya RV, Pisegna JR, Venzon DJ, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119:199-206.
22. Sugg SL, Norton JA, Fraker DL, Metz DC, Pisegna JR, et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg. 1993;218:138-144.
23. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615-630.
24. Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410-419.
25. Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg. 1994;220:320-330.